Latest Hotspot

SCG Cell Therapy finds that SCG101 boosts tumor response and sustains antiviral effects in advanced liver cancer patients with HBV

22 November 2023
3 min read

Late clinical results were unveiled by SCG Cell Therapy Pte Ltd,, a biotechnological firm in the clinical phase developing fresh immunotherapies against infectious diseases and related cancers, at the 2023 AASLD Liver Meeting in Boston, USA. This groundbreaking data derives from SCG101, their pioneering autologous HBV-specific T-cell receptor-engineered T Cell treatment - a first in its class.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Clinical trial data from the first human trials reveals promising antiviral and antitumor activity in advanced HBV-related hepatocellular carcinoma patients using SCG101. Out of six patients who received a single IV dose of SCG101 at 5.0×107 ~ 1.0×108 TCR+ T cells/kg, there were partial responses in two patients, and two patients saw stabilizing conditions with observable tumor reduction.

Strong correlations were observed between the antiviral activity of SCG101 and the tumor responses. As per the cutoff data, serum HBsAg reduction was experienced by all six patients, with four achieving a reduction of 1~3 log post-SCG101 infusion.

The safety evaluation showed that SCG101 was generally well tolerated, with no serious incidents of adverse effects or neurotoxicity syndrome linked to immune effector cells. The adverse effects related to the treatment, such as transient liver enzymes evaluation, cytokine release syndrome, and fever, were anticipated due to the working mechanism of SCG101 on diseased hepatocytes clearance and immune activation.

SCG101 has the ability to precisely target an HBV peptide presented on HBV-HCC tumor cells, premalignant hepatocytes integrated with HBV-DNA and cells infected with HBV, thereby initiating cytolytic and non-cytolytic methods to eradicate tumor cells and HBV-infected cells.

Frank Wang, the CEO of SCG Cell Therapy stated, "We are thrilled to lead in illustrating the potential of HBV TCR T cell therapy in obtaining promising tumor responses in solid tumors, as well as inducing lasting antiviral activity. This distinctive double function of SCG101 introduces a fresh approach to treat HBV-associated HCC by targeting the root cause of the cancer."

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面

描述已自动生成

According to the data provided by the Synapse Database, As of November 21, 2023, there are 38 investigational drugs for the HBsAg target, including 14 indications, 42 R&D institutions involved, with related clinical trials reaching 225, and as many as 6706 patents.

SCG101, an autologous T-cell receptor T cell therapy, is an investigational cell therapy product targeting a specific epitope of hepatitis B surface antigen (HBsAg). SCG101 was granted clinical trial approvals by FDA, NMPA and Singapore Health Science Authority and Hong Kong Department of Health for patients with HBV-related HCC.

图形用户界面, 文本

描述已自动生成

An analysis of BNT-116's R&D progress and its clinical results presented at the 2023 SITC
An analysis of BNT-116's R&D progress and its clinical results presented at the 2023 SITC
22 November 2023
BNT116 is an intravenously administered RNA-lipoplex therapeutic cancer vaccine comprising six RNAs each encoding a tumor-associated antigen (TAA) frequently expressed in non-small cell lung cancer (NSCLC).
Read →
Ionetix will supply Bayer with Actinium-225 (Ac-225), a therapeutic radioisotope
Latest Hotspot
3 min read
Ionetix will supply Bayer with Actinium-225 (Ac-225), a therapeutic radioisotope
22 November 2023
Ionetix Corporation has publicized that it has entered into a supply contract for the therapeutic radioisotope actinium-225 (Ac-225) with Bayer.
Read →
Alpine Immune Sciences reveals new study results for Lupus treatment at 2023 Rheumatology Convergence
Latest Hotspot
3 min read
Alpine Immune Sciences reveals new study results for Lupus treatment at 2023 Rheumatology Convergence
22 November 2023
Alpine Immune Sciences unveils fresh Acazicolcept study results for Systemic Lupus Erythematosus at 2023 Rheumatology Convergence by American College.
Read →
Decoding LY-3410738: a comprehensive study of its R&D trends and its clinical results in 2023 AACR
Decoding LY-3410738: a comprehensive study of its R&D trends and its clinical results in 2023 AACR
20 November 2023
The phase 1 trial of LY3410738, a covalent mutant IDH inhibitor, in advanced IDH-mutant CCAs and other tumors was presented at the AACR Congress, paving the way for further outcome evaluation.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.